Results 1 to 10 of about 1,853,062 (297)
The International Journal of Biological Markers, 1998 CA 125 is not a specific tumor marker, and is synthesized by normal and malignant cells of different origin (mainly in tissues derived from the müllerian epithelia) in a similar proportion.
R. Molina +4 more
doaj +4 more sources
CA 125: The past and the Future
The International Journal of Biological Markers, 1998 Over the last 15 years, substantial progress has been made in understanding the potential and the limitations of the CA 125 assay. More than 2000 papers have been published concerning laboratory and clinical studies of CA 125.
R.C. Bast +5 more
doaj +4 more sources
CA 125 in Benign Gynecological Conditions
The International Journal of Biological Markers, 1998 The tumor marker CA 125 was initially thought to be specific for ovarian malignancies. Subsequently it was found to be raised in a variety of benign conditions, including pregnancy, pelvic inflammatory disease, tuberculosis and cirrhosis of the liver ...
H. Meden, A. Fattahi-Meibodi
doaj +4 more sources
CA 125 - Epitopes and Molecular Size
The International Journal of Biological Markers, 1998 CA 125 has two main immunogenic areas reactive with mouse and rat monoclonal antibodies. These areas are defined by the antibodies OC 125 and M11, respectively. Antibodies related to the main groups are named OC 125-like and M 11-like antibodies.
K. Nustad +3 more
doaj +3 more sources
Carbohydrate Antigen 125 (CA 125): A Novel Biomarker in Acute Heart Failure [PDF]
DiagnosticsBackground: Heart failure is a global major healthcare problem with millions of hospitalizations annually and with a very high mortality. There is an increased interest in finding new and reliable biomarkers for the diagnostic, prognostic and therapeutic
Mihai Cristian Marinescu +6 more
doaj +2 more sources
Recurrent patterns and prognostic factors based on CA-125 and RECIST progression in ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors [PDF]
Journal of Ovarian ResearchBackground Response Evaluation Criteria in Solid Tumors (RECIST) and CA-125 criteria are widely used to evaluate disease progression (PD) in ovarian cancer patients undergoing chemotherapy.
Bingxin Zhang +7 more
doaj +2 more sources
Distribution of CA 125 in Placental Tissues
The International Journal of Biological Markers, 1989 The presence of the tumor marker CA 125 was studied in different compartments of the human placenta. Levels of CA 125 in the cytosol of chorionic villi ranged from 27 - 17100 U/g (median 560 U/g). In the placental amnion and chorion concentrations ranged
L.C. Fuith +5 more
doaj +3 more sources
Longitudinal evaluation of external quality assessment results for CA 15-3, CA 19-9, and CA 125 [PDF]
Frontiers in Molecular BiosciencesBackgroundTumor markers are established laboratory tools that help to diagnose, estimate prognosis, and monitor the course of cancer. For meaningful decision-making in patient care, it is essential that methods and analytical platforms demonstrate high ...
Marcel Kremser +8 more
doaj +2 more sources
CA 125 Elevation: A Descriptive Etiological Study [PDF]
National Journal of Laboratory Medicine, 2016 Introduction: CA 125 (Cancer/Carbohydrate antigen 125) is a surface antigen expressed mostly by the ovarian cancer cells. Hence, it is widely used as a tumour marker for detection and monitoring the progression of such cancers.
Shaheena Appan Parambath +6 more
doaj +1 more source
CA 125: History, Current Status, and Future Prospects
McGill Journal of Medicine, 2020 N ...
Robert C., Jr Bast, Robert C. Knapp
doaj +1 more source